CD8+ T Cell Therapy and Pembrolizumab in Treating Patients With Metastatic Gastrointestinal Tumors
Status:
Terminated
Trial end date:
2020-10-02
Target enrollment:
Participant gender:
Summary
This phase I pilot trial studies the side effects of cluster of differentiation 8 (CD8)+ T
cells in treating patients with gastrointestinal tumors that have spread to other places in
the body. Tumor cells and blood are used to help create an adoptive T cell therapy, such as
CD8+ T cell therapy, that is individually designed for a patient and may help doctors learn
more about genetic changes in the tumor. Immunotherapy with monoclonal antibodies, such as
pembrolizumab, may help the body's immune system attack the cancer, and may interfere with
the ability of tumor cells to grow and spread. Giving CD8+ T cell therapy and pembrolizumab
may work better in treating patients with gastrointestinal tumors.
Phase:
Phase 1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborators:
Merck Sharp & Dohme Corp. National Cancer Institute (NCI)